论文部分内容阅读
最近英国威尔士大学附属医院药剂师设计了一种新的5-氨基水杨酸(5-ASA)口服制剂。这种药物可以克服柳氮磺胺吡啶对结肠炎病人的副作用。在临床试验中其疗效鼓舞人心,又易被病人接受。柳氮磺胺吡啶广泛用于溃疡性结肠炎病人的维持治疗。但由于不良作用和变态反应,一些患者难以接受。柳氮磺胺吡啶是由5-ASA和磺胺吡啶通过偶氮键结合而成,在结肠中经细菌裂解而生成两种化合物。据认为是5-ASA发挥治疗作用,而磺胺吡啶不过是
Recently, the University of Wales Hospital Pharmacist designed a new 5-aminosalicylic acid (5-ASA) oral preparation. This drug overcomes the side effects of sulfasalazine on colitis patients. In clinical trials its effect is inspiring, but also easily accepted by patients. Sulfasalazine is widely used in the maintenance treatment of patients with ulcerative colitis. However, some patients are unacceptable due to adverse effects and allergies. Sulfasalazine is formed by the combination of 5-ASA and sulfapyridine via an azo bond, which is cleaved in the colon to produce two compounds. It is thought that 5-ASA plays a therapeutic role, whereas sulfadiazine is nothing more than that